Welcome to our dedicated page for BioSig Technologies news (Ticker: BSGM), a resource for investors and traders seeking the latest updates and insights on BioSig Technologies stock.
BioSig Technologies Inc. (NASDAQ: BSGM) provides cutting-edge solutions in cardiac electrophysiology through its flagship PURE EP™ System. This page serves as the definitive source for official company news, including financial results, regulatory milestones, and clinical advancements.
Investors and healthcare professionals will find curated updates on product innovations, partnership announcements, and peer-reviewed research validating BioSig's signal processing technology. Key coverage areas: quarterly earnings reports, FDA clearances, hospital adoption metrics, and intellectual property developments.
All content undergoes strict verification to ensure alignment with SEC disclosure standards and medical device reporting regulations. Bookmark this page for real-time updates on BSGM's progress in enhancing cardiac ablation accuracy through advanced signal visualization technology.
BioSig Technologies CEO, Anthony Amato, has issued a letter to shareholders detailing recent advancements and future plans for the company. Over the past two months, BioSig has appointed a new, experienced Board of Directors and is forming a Business Advisory Board to assess business opportunities and potential mergers. The company remains focused on its core PURE EP™ Biomedical Signal Processing Technology and is actively pursuing AI-related initiatives. BioSig has regained compliance with Nasdaq's minimum bid price requirement and presented to the Nasdaq Hearings Panel to address other compliance issues. The company is optimistic about its growth prospects and is committed to enhancing shareholder value.
BioSig Technologies, Inc. announced new appointments to its board of directors, now fully constituted with 5 members, 3 independent. The company aims for compliance with U.S. Exchange regulations, bringing in directors with diverse industry experience to create lasting shareholder value.
BioSig Technologies, Inc. appointed Mr. Anthony Amato as the Chief Executive Officer and member of the Board of Directors to accelerate the implementation of a comprehensive turnaround strategy. Mr. Amato brings a wealth of experience in business leadership and management. The Company aims to unlock substantial value through its core product line, PURE EP™, and plans to update shareholders on further developments.
FAQ
What is the current stock price of BioSig Technologies (BSGM)?
What is the market cap of BioSig Technologies (BSGM)?
